Michael G. Kauffman

Dr. Kauffman has over 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development, and regulatory strategy. In addition to Adicet, he is a board member for Karyopharm Therapeutics, Verastem Oncology, and Kezar Life Sciences. Most recently, Dr. Kauffman served as the co-founder and chief executive officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial-stage organization. Prior to joining Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. Previously, Dr. Kauffman was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School and is board-certified in Internal Medicine.